

Commercial and Other Pharmacy Program Updates Effective January 2021

The following changes to our pharmacy programs will become effective **Jan. 1, 2021**. The changes affect our preferred drug lists and medication guides, including prior authorization requirements, the Responsible Quantity Program, Responsible Steps and the Pharmacy Coverage Exclusions List. Important changes are summarized below.

Preferred Drug List Changes and Medication Guides

Changes to our preferred drug lists and the current list are available at floridablue.com/providers. Select **Tools & Resources**, **Medical & Pharmacy Policies, Guidelines**, then **Medication Guides**. Here is the direct link to the [Medication Guides](#).

Medications Requiring Prior Authorization

Prior authorization requirements for the following list of medications will change under the member's pharmacy benefits. This applies only to members whose plans are part of the Prior Authorization Program. New-to-market drugs may still be under review for a coverage decision as a part of our New-to-Market Program.

Drugs Added to the Prior Authorization Program	
Drug	Covered Condition(s)*
Bafiertam	FDA-approved indication(s)
Cystadrops	FDA-approved indication(s)
Cystaran	FDA-approved indication(s)
Dojolvi	FDA-approved indication(s)
Enspryng	FDA-approved indication(s)
Fintepla	FDA-approved indication(s)
Gavreto	FDA-approved indication(s)
Inqovi	FDA-approved indication(s)
Kesimpta	FDA-approved indication(s)
Lupron	FDA-approved indication(s)
Mycapssa	FDA-approved indication(s)
Northera	FDA-approved indication(s)
Onureg	FDA-approved indication(s)

Sevenfact	FDA-approved indication(s)
Xywav	FDA-approved indication(s)
Zerviate	FDA-approved indication(s)
*Summary of criteria and additional information are available with our authorization forms.	

Responsible Quantity Program

We will add the following drugs and drug-dispensing limits to the Responsible Quantity Program effective Jan. 1, 2021. This applies only to members enrolled in plans that participate in the Responsible Quantity Program. **Please note:** Responsible Quantity Program limits apply to generic drugs where applicable.

Drugs Added to the Responsible Quantity Program		
Brand/Generic Name	Strength	Dispensing Limit Per Month (unless noted otherwise)
Airduo Digihaler		1 inhaler
Armonair Digihaler		1 inhaler
Breztri Aerosphere		1 inhaler
Omnipod/Dash		6 box
Omnipod/Dash Starter Kit		1 kit / 365 days
Tolak		40 grams / 28 days
Trulicity	3 mg, 4.5 mg	4 pens / 28 days
V-Go		1 kit
Updates to Drugs Already in the Responsible Quantity Program		
Brand/Generic Name	Strength	Dispensing Limit Per Month (unless noted otherwise)
Tivicay	10mg	240 tabs

New Pharmacy Coverage Exclusions

Our commercial pharmacy plans will no longer cover the brand-name or generic drugs listed below. We will cover many of their therapeutic or generic alternatives. This exclusion list applies only to members enrolled in health plans that allow pharmacy coverage exclusions.

New Coverage Exclusions	
Azeschew	Patanol
Dayvigo	Pataday
Diclofenac ER 100mg tab	Phexxi
Ferriprox Twice-a-day	Prenara
Kombiglyze XR	Prenatrix
Licart	Proair HFA/Proair Respclick

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

103842 1120

Lidocaine 2% gel	Ranitidine products
Lyumjev	Tecfidera brand
Migranal nasal Spray	Trinaz
Minocycline tablets	Twirla
Nexium brand granules	Voltaren gel
Onglyza	Vumerity
Ortikos	Zilxi
Drugs Added Back to Coverage	
Zerviate	

Net Results Formulary Program Updates

The following changes only apply to members with the Net Results formulary as part of their plan.

Net Results Quantity Limit Program

The following drugs and drug-dispensing limits to the Net Results Quantity Limit Program become effective Jan. 1, 2021.

Brand/Generic Name	
AirDuo Digihaler	Rukobia
Armonair Digihaler	Semglee
Breztri	Symfi
Emtriva	Symfi Lo

Net Results Medications Requiring Prior Authorization

Prior authorization requirements for the following list of medications will change for members using our Net Results Formulary effective Jan. 1, 2021.

Drugs Added to the Net Results Prior Authorization Program	
Drug	Covered Condition(s)*
Bafiertam	FDA-approved indication(s)
Dojolvi	FDA-approved indication(s)
Fintepla	FDA-approved indication(s)
Gavreto	FDA-approved indication(s)
Inqovi	FDA-approved indication(s)
Kesimpta	FDA-approved indication(s)
Onureg	FDA-approved indication(s)
Xywav	FDA-approved indication(s)
*Summary of criteria and additional information are available with authorization forms available at myprime.com	

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

103842 1120

Net Results Step Therapy Program Changes

The following changes apply to the Step Therapy Program.

Program	Net Results Program Change
Continuous Glucose Monitors	Freestyle Libre 2
Rho Kinase Inhibitors	Addition of Rhopressa and Rocklatan

Net Results Pharmacy Coverage Exclusions

Effective Jan. 1, 2021, Net Results will no longer cover the brand-name or generic drugs listed below.

Net Results New Exclusions	
Allopurinol tab 300mg	Migranal spray
Byfenzia pen	Minocycline tabs
Daraprim	Minocycline ER tabs
Darzalex Faspro	Mycapssa
Dayvigo	Nexium packets
Diclofenac gel 1%	Olopatidine 0.1%
Diclofenac tab ER 100mg	Onglyza
Dojolvi	Ortikos
Durista	Phesgo
Fensolvi	Phexxi
Ferriprox twice-a-day	Proair HFA/ Proair Resplick
Jemlyto	Proglycem
Kombiglyze XR	Samsca
Lamotrigine orally disintegrating tabs	Tecfidera/ Tecfidera starter pack
Licart	Twirla
Lyumjev	Vumerity
Net Results Drugs Added Back to Coverage	
Esperoct	Rocklatan
Jivi	Trijardy XR
Rhopressa	

Net Results Authorization Request Forms

Net Results authorization request forms are available at myprime.com. Create a profile or click on **Forms** and then select **Continue without sign in**. Select **Florida Blue** from the top dropdown menu and **No** to the question regarding Medicare status. At the top of the following page, click **Forms** and then select **Florida Blue Net Results Formulary**. You will see a list of form categories.

Verify Eligibility and Benefits on Availity

As a reminder, you can verify your patients' eligibility and pharmacy benefits through Availity^{®1} at [availity.com](https://www.availity.com). If you have questions about your patients' Florida Blue benefits or these pharmacy updates, please call the Provider Contact Center at 800-727-2227.

¹Availity, LLC is a multi-payer joint venture company. For more information, visit [availity.com](https://www.availity.com).